RxDoctor Payments Data

Christian Reyna, DO

Internal Medicine · Sacramento, CANPI 1669727046

Payments from drug & device makers

$4,609in general payments, 2019–2025

Across 218 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$616
  • GSK$544
  • Pfizer$473
  • Novo Nordisk$278
  • AbbVie$265
  • Otsuka America Pharmaceutical, Inc.$176
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,57599%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,609 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$152,854
Medicare patients
328
Services billed
1,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide54$86,286
EliquisApixaban151$65,057
MounjaroTirzepatide18$23,352
JardianceEmpagliflozin48$23,258
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,605
MyrbetriqMirabegron43$14,690
FarxigaDapagliflozin Propanediol11$11,528
Sucralfate43$6,593
XareltoRivaroxaban13$5,547
Doxepin Hcl12$5,070
LinzessLinaclotide12$4,924
Divalproex Sodium34$3,198
Atorvastatin Calcium281$2,805
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen124$2,178
Levothyroxine Sodium182$2,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$278$86,28654 claims
PfizerEliquis$473$65,057151 claims
Lilly USA, LLCMounjaro$138$23,35218 claims
Boehringer IngelheimJardiance$130$23,25848 claims
GSKTrelegy Ellipta$544$17,60521 claims
AstraZenecaFarxiga$616$11,52811 claims
AbbVieLinzess, Synthroid$265$5,71724 claims
Johnson & JohnsonXarelto$150$5,54713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →